Search results
Robert W. Baird Cuts Calidi Biotherapeutics (NYSEAMERICAN:CLDI) Price Target to $2.00
ETF DAILY NEWS· 3 days agoCalidi Biotherapeutics (NYSEAMERICAN:CLDI – Free Report) had its price objective decreased by Robert W. Baird from $4.50 to $2.00 in a research note published on Wednesday ...
Verastem (NASDAQ:VSTM) Stock Price Crosses Above 200-Day Moving Average of $10.14
ETF DAILY NEWS· 22 hours agoVerastem, Inc. (NASDAQ:VSTM – Get Free Report) crossed above its 200-day moving average during trading on Monday . The stock has a 200-day moving average of $10.14 and traded as high as $11.88 ...
Q1 2024 TRACON Pharmaceuticals Inc Earnings Call
Thomson Reuters StreetEvents via Yahoo Finance· 7 days agoAt this time, Scott will provide an update on our financials. Scott Brown Thank you, Charles, and good afternoon, everyone. TRACON's research and development expenses were $1.9 million for the ...
MiNK Therapeutics Inc (INKT) Q1 2024 Earnings Call Transcript Highlights: Strategic Reductions ...
GuruFocus.com via Yahoo Finance· 7 days agoA: Jennifer Buell responded that MiNK-215 will initially focus on SAP-expressing tumors, particularly in colorectal cancers and non-small cell lung cancer
Calidi Biotherapeutics (NYSEAMERICAN:CLDI) PT Lowered to $2.00 at Robert W. Baird
ETF DAILY NEWS· 3 days agoCalidi Biotherapeutics (NYSEAMERICAN:CLDI – Free Report) had its price target reduced by Robert W. Baird from $4.50 to $2.00 in a report released on Wednesday, Benzinga reports ...
BioAtla Inc (BCAB) (Q1 2024) Earnings Call Transcript Highlights: Strategic Adjustments and ...
GuruFocus.com via Yahoo Finance· 7 days agoAnd also, do you expect to start the next stage of recruiting in 2024 or it could be in early 2025? A: (Sheri Lydick...received from physicians on the CAB-AXL ADC data in ...
Sonnet BioTherapeutics Announces Updated Clinical Data for SON-1010 as Monotherapy or Combined with...
Morningstar· 1 day agoPRINCETON, NJ / ACCESSWIRE / May 20, 2024 / Sonnet BioTherapeutics Holdings, Inc. (NASDAQ:SONN) (the "Company" or "Sonnet"), a clinical-stage company developing targeted immunotherapeutic ...
HC Wainwright Reaffirms Buy Rating for BioAtla (NASDAQ:BCAB)
ETF DAILY NEWS· 4 days agoHC Wainwright restated their buy rating on shares of BioAtla (NASDAQ:BCAB – Free Report) in a research report released on Wednesday, Benzinga reports. They currently have a $7.00 price target ...
Adaptimmune Therapeutics (NASDAQ:ADAP) PT Lowered to $3.00 at Mizuho
ETF DAILY NEWS· 5 days agoAdaptimmune Therapeutics (NASDAQ:ADAP – Get Free Report) had its price target cut by research analysts at Mizuho from $9.00 to $3.00 in a research report issued on Friday, Benzinga reports.
